Attenuation of electrical remodelling in chronic atrial fibrillation following oral treatment with verapamil
Electrical remodelling with shortening of the atrial refractory period and increased fibrillatory rate occurs after onset of atrial fibrillation and can be attenuated by pre-treatment with intravenous verapamil. The aim of the present study was to investigate whether already established fibrillatory...
Saved in:
Published in | Europace (London, England) Vol. 1; no. 4; pp. 234 - 241 |
---|---|
Main Authors | , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
England
01.10.1999
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Electrical remodelling with shortening of the atrial refractory period and increased fibrillatory rate occurs after onset of atrial fibrillation and can be attenuated by pre-treatment with intravenous verapamil. The aim of the present study was to investigate whether already established fibrillatory-induced shortening of atrial fibrillatory cycle length could be reversed with oral verapamil.
Thirteen patients (nine men; mean age 67 years) with chronic atrial fibrillation (CAF) were studied. The dominant atrial cycle length (DACL) was estimated non-invasively using the frequency analysis of fibrillatory ECG (FAF-ECG) method. Measurements were repeated following treatment with slow release oral verapamil. DACL increased from 147 +/- 13 ms to 156 +/- 21 ms after 1 day (P=0.02), to 164 +/- 18 ms after 5 days (P=0.005) and finally to 160 +/- 16 ms after 6 weeks (P=0.008).
Long-term oral treatment with verapamil increases the DACL significantly in patients with CAF. The prolongation is evident after 1 day and is further developed during the first 5 days of treatment. Since DACL is believed to be an index of refractoriness, the findings of the present study suggest that this treatment increases the atrial refractory period in patients with CAF. |
---|---|
AbstractList | AIMS: Electrical remodelling with shortening of the atrial refractory period and increased fibrillatory rate occurs after onset of atrial fibrillation and can be attenuated by pre-treatment with intravenous verapamil. The aim of the present study was to investigate whether already established fibrillatory-induced shortening of atrial fibrillatory cycle length could be reversed with oral verapamil. METHODS AND RESULTS: Thirteen patients (nine men; mean age 67 years) with chronic atrial fibrillation (CAF) were studied. The dominant atrial cycle length (DACL) was estimated non-invasively using the frequency analysis of fibrillatory ECG (FAF-ECG) method. Measurements were repeated following treatment with slow release oral verapamil. DACL increased from 147 +/- 13 ms to 156 +/- 21 ms after 1 day (P=0.02), to 164 +/- 18 ms after 5 days (P=0.005) and finally to 160 +/- 16 ms after 6 weeks (P=0.008). CONCLUSION: Long-term oral treatment with verapamil increases the DACL significantly in patients with CAF. The prolongation is evident after 1 day and is further developed during the first 5 days of treatment. Since DACL is believed to be an index of refractoriness, the findings of the present study suggest that this treatment increases the atrial refractory period in patients with CAF. AIMSElectrical remodelling with shortening of the atrial refractory period and increased fibrillatory rate occurs after onset of atrial fibrillation and can be attenuated by pre-treatment with intravenous verapamil. The aim of the present study was to investigate whether already established fibrillatory-induced shortening of atrial fibrillatory cycle length could be reversed with oral verapamil.METHODS AND RESULTSThirteen patients (nine men; mean age 67 years) with chronic atrial fibrillation (CAF) were studied. The dominant atrial cycle length (DACL) was estimated non-invasively using the frequency analysis of fibrillatory ECG (FAF-ECG) method. Measurements were repeated following treatment with slow release oral verapamil. DACL increased from 147 +/- 13 ms to 156 +/- 21 ms after 1 day (P=0.02), to 164 +/- 18 ms after 5 days (P=0.005) and finally to 160 +/- 16 ms after 6 weeks (P=0.008).CONCLUSIONLong-term oral treatment with verapamil increases the DACL significantly in patients with CAF. The prolongation is evident after 1 day and is further developed during the first 5 days of treatment. Since DACL is believed to be an index of refractoriness, the findings of the present study suggest that this treatment increases the atrial refractory period in patients with CAF. Electrical remodelling with shortening of the atrial refractory period and increased fibrillatory rate occurs after onset of atrial fibrillation and can be attenuated by pre-treatment with intravenous verapamil. The aim of the present study was to investigate whether already established fibrillatory-induced shortening of atrial fibrillatory cycle length could be reversed with oral verapamil. Thirteen patients (nine men; mean age 67 years) with chronic atrial fibrillation (CAF) were studied. The dominant atrial cycle length (DACL) was estimated non-invasively using the frequency analysis of fibrillatory ECG (FAF-ECG) method. Measurements were repeated following treatment with slow release oral verapamil. DACL increased from 147 +/- 13 ms to 156 +/- 21 ms after 1 day (P=0.02), to 164 +/- 18 ms after 5 days (P=0.005) and finally to 160 +/- 16 ms after 6 weeks (P=0.008). Long-term oral treatment with verapamil increases the DACL significantly in patients with CAF. The prolongation is evident after 1 day and is further developed during the first 5 days of treatment. Since DACL is believed to be an index of refractoriness, the findings of the present study suggest that this treatment increases the atrial refractory period in patients with CAF. |
Author | Meurling, C J Stridh, M Ingemansson, M P Roijer, A Carlson, J Lindholm, C J Smideberg, B Olsson, S B Sornmo, L |
Author_xml | – sequence: 1 givenname: C J surname: Meurling fullname: Meurling, C J organization: Department of Cardiology, Lund University, Sweden – sequence: 2 givenname: M P surname: Ingemansson fullname: Ingemansson, M P – sequence: 3 givenname: A surname: Roijer fullname: Roijer, A – sequence: 4 givenname: J surname: Carlson fullname: Carlson, J – sequence: 5 givenname: C J surname: Lindholm fullname: Lindholm, C J – sequence: 6 givenname: B surname: Smideberg fullname: Smideberg, B – sequence: 7 givenname: L surname: Sornmo fullname: Sornmo, L – sequence: 8 givenname: M surname: Stridh fullname: Stridh, M – sequence: 9 givenname: S B surname: Olsson fullname: Olsson, S B |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/11220560$$D View this record in MEDLINE/PubMed https://lup.lub.lu.se/record/1116098$$DView record from Swedish Publication Index |
BookMark | eNpFkTuv1DAQhV1cxH1AS4lS0e0yfiSxy6srXtJKNFBbjjPmGjl2sB1W_Hsc7QqK0Wh0zpyR5rsnNzFFJOQNhSOFnr_HbbVHqpQ6AvT9DbmjoNShp0zdkvtSfgLAyFT_ktxSyhj0A9yR8Fgrxs1Un2KXXIcBbc3emtBlXNKMIfj4o_Oxs885RW870-SmOj9lH8Jl0aUQ0nk3pty0mtHUBWPtzr4-d78xm9UsPrwiL5wJBV9f-wP5_vHDt6fPh9PXT1-eHk8HKwDqwaFDNUmrBOPC0rlNiNxSmA0MRs7S8WlU3BqDlCIKOY1oqeEWlECqRv5ATpfccsZ1m_Sa_WLyH52M12FbW02tdEEtqFOGDVxzKUCLgaGW6JiWnMrBDqKXYo97d4lbc_q1Yal68cW2z5iIaSt6UD2MiqlmPF6MNqdSMrp_lynoHZHeEekdkd4RtYW31-RtWnD-b7_y4X8BMZiTqg |
CitedBy_id | crossref_primary_10_1016_j_ccep_2010_10_003 crossref_primary_10_1016_j_jelectrocard_2012_09_002 crossref_primary_10_1109_TBME_2005_862567 crossref_primary_10_1007_s10557_005_5062_z crossref_primary_10_1098_rsta_2008_0162 crossref_primary_10_1111_j_1540_8159_2006_00469_x crossref_primary_10_1093_europace_eut251 crossref_primary_10_1093_europace_eul113 crossref_primary_10_1152_ajpheart_00075_2005 crossref_primary_10_1016_j_ejim_2008_07_001 crossref_primary_10_1109_TBME_2008_2006624 crossref_primary_10_1111_j_1540_8159_2006_00386_x crossref_primary_10_1016_S0002_9149_02_02690_5 crossref_primary_10_1093_europace_eun195 crossref_primary_10_1093_europace_euu249 crossref_primary_10_1093_europace_eul072 crossref_primary_10_1111_j_1542_474X_2002_tb00148_x crossref_primary_10_1186_1471_2261_6_11 crossref_primary_10_1046_j_1365_2796_2001_00853_x crossref_primary_10_1016_j_amjcard_2004_10_025 crossref_primary_10_1016_j_jelectrocard_2015_07_019 crossref_primary_10_1046_j_1540_8167_90305_x |
ContentType | Journal Article |
DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 ADTPV AGCHP AOWAS D8T D95 ZZAVC |
DOI | 10.1053/eupc.1999.0055 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef MEDLINE - Academic SwePub SWEPUB Lunds universitet full text SwePub Articles SWEPUB Freely available online SWEPUB Lunds universitet SwePub Articles full text |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EndPage | 241 |
ExternalDocumentID | oai_lup_lub_lu_se_41f9a263_3840_462e_8ef2_83186c645847 10_1053_eupc_1999_0055 11220560 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GroupedDBID | --- --K .2P .I3 .XZ .ZR 0R~ 1B1 1TH 29G 2WC 4.4 48X 53G 5GY 5VS 5WA 6PF 70D AABZA AACZT AAJKP AAJQQ AAMVS AAOGV AAPNW AAPQZ AAPXW AASNB AAUAY AAUQX AAVAP AAWTL ABEUO ABIXL ABJNI ABKDP ABNHQ ABNKS ABPTD ABQLI ABQTQ ABWST ABXVV ABZBJ ACGFS ACPRK ACUFI ACUTO ADBBV ADEYI ADEZT ADGZP ADHKW ADHZD ADJQC ADOCK ADRIX ADRTK ADVEK ADYVW ADZXQ AEGPL AEJOX AEKSI AEMDU AENEX AENZO AEPUE AETBJ AEWNT AFFZL AFIYH AFOFC AFXAL AFXEN AGINJ AGKEF AGQXC AGSYK AGUTN AHMBA AHXPO AIJHB AJEEA ALMA_UNASSIGNED_HOLDINGS ALUQC APIBT APWMN ATGXG AXUDD BAWUL BAYMD BCRHZ BEYMZ BHONS BTRTY BVRKM C1A CAG CDBKE CGR COF CS3 CUY CVF CZ4 DAKXR DIK DILTD DU5 D~K E3Z EBD EBS ECM EE~ EIF EJD EMOBN ENERS F5P F9B FECEO FLUFQ FOEOM FOTVD FQBLK GAUVT GJXCC GX1 H13 H5~ HAR HW0 HZ~ IHE IOX J21 KBUDW KOP KQ8 KSI KSN M-Z M41 M49 MHKGH N9A NGC NOMLY NOYVH NPM NQ- NTWIH NU- O0~ O9- OAUYM OAWHX ODMLO OJQWA OJZSN OK1 OPAEJ OVD P2P PAFKI PEELM PQQKQ Q1. Q5Y RD5 RHF RIG ROL ROX RPM RPZ RUSNO RW1 RXO SEL SV3 TCURE TEORI TJX TOX TR2 UHS VVN W8F WOQ X7H YAYTL YKOAZ YXANX ZKX ~91 AAYXX CITATION 7X8 ADTPV AGCHP AOWAS D8T D95 ZZAVC |
ID | FETCH-LOGICAL-c400t-fefe9b8c94234c1dfe9ee3c10da06a8d8f3b793caae11ee48b7ec1a3c094e1973 |
ISSN | 1099-5129 1532-2092 |
IngestDate | Sat Aug 24 00:18:33 EDT 2024 Fri Aug 16 04:47:05 EDT 2024 Fri Aug 23 03:37:26 EDT 2024 Sat Sep 28 08:37:40 EDT 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 4 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c400t-fefe9b8c94234c1dfe9ee3c10da06a8d8f3b793caae11ee48b7ec1a3c094e1973 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
OpenAccessLink | https://lup.lub.lu.se/record/1116098 |
PMID | 11220560 |
PQID | 69507929 |
PQPubID | 23479 |
PageCount | 8 |
ParticipantIDs | swepub_primary_oai_lup_lub_lu_se_41f9a263_3840_462e_8ef2_83186c645847 proquest_miscellaneous_69507929 crossref_primary_10_1053_eupc_1999_0055 pubmed_primary_11220560 |
PublicationCentury | 1900 |
PublicationDate | 1999-10-01 |
PublicationDateYYYYMMDD | 1999-10-01 |
PublicationDate_xml | – month: 10 year: 1999 text: 1999-10-01 day: 01 |
PublicationDecade | 1990 |
PublicationPlace | England |
PublicationPlace_xml | – name: England |
PublicationTitle | Europace (London, England) |
PublicationTitleAlternate | Europace |
PublicationYear | 1999 |
SSID | ssj0007295 |
Score | 1.7181509 |
Snippet | Electrical remodelling with shortening of the atrial refractory period and increased fibrillatory rate occurs after onset of atrial fibrillation and can be... AIMSElectrical remodelling with shortening of the atrial refractory period and increased fibrillatory rate occurs after onset of atrial fibrillation and can be... AIMS: Electrical remodelling with shortening of the atrial refractory period and increased fibrillatory rate occurs after onset of atrial fibrillation and can... |
SourceID | swepub proquest crossref pubmed |
SourceType | Open Access Repository Aggregation Database Index Database |
StartPage | 234 |
SubjectTerms | Aged Anti-Arrhythmia Agents - pharmacology Anti-Arrhythmia Agents - therapeutic use arrhythmia Atrial fibrillation Atrial Fibrillation - drug therapy Atrial Fibrillation - physiopathology Blood Pressure - drug effects Ca-channel Cardiac and Cardiovascular Systems Chronic Disease Clinical Medicine Female Heart Conduction System - drug effects Heart Rate - drug effects Humans Kardiologi Klinisk medicin Male Medical and Health Sciences Medicin och hälsovetenskap Middle Aged remodelling verapamil Verapamil - pharmacology Verapamil - therapeutic use |
Title | Attenuation of electrical remodelling in chronic atrial fibrillation following oral treatment with verapamil |
URI | https://www.ncbi.nlm.nih.gov/pubmed/11220560 https://search.proquest.com/docview/69507929 https://lup.lub.lu.se/record/1116098 |
Volume | 1 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3ri9QwEA96gvhFfLs-80Hwg1TbJn19PHSPu_P2BNmF_RaSdContV32WgX_eidJX-se-PjQ0AeEMvNjMpnM_IaQVwwxkDIuPc4T7fG8UJ5Mct9TQSHRe-bMz0018uI8Pl7x03W0HhMybXVJo97qn1fWlfyPVvEd6tVUyf6DZodJ8QXeo35xRA3j-Fc6PmzQ420Hp8-1tLFS34JtcVN2FSvaUeC-ka5JR2Hy_MuyzzMsy_qHTX7e7mSe2xDtd1OeZYIgeyF8qeHKfiCT2MICWkOmZa3J5ADqpPoC33CJ7Iq9FmON2ef64mvXXns8HNn2hJKnY4jC0hr0yW69VTU0oMaz2DG7E3TxqQntgptuNQ4dLdaeofdttw5oN9rUWxrOUcf2u8uoff5JHK3OzsRyvl5eJzfCJIvMBv3DycdhtcbNRWRPxLtf7Ik9I_Zud_Zdx2VvN_Ib1ax1T5Z3yO1uX0EPHUjukmtQ3SM3F13mxH1STrBC64KOWKETrNCLinZYoQ4rdIoVOmCFGqzQASvUYIUOWHlAVkfz5ftjr-u04Wm04Y1XQAGZSnWGzjXXQY5PAEwHfi79WKZ5WjCFhlxLCUEAwFOVgA4k037GIcgS9pAcVHUFjwnVPNJxqHDMGc8TJRNAn7xQzDRE4gAz8roXo9g4QhVhEyEiJozAhRG4MAKfkZe9lAXaPHOQJSuo20sRZ7iLQb9-Rh454Y8zBaZwPPZnZO60MXwxNOplu8FL4SUuQfCgyGQYM8FS7gsehyBSKEKR4jIX69gmEDz54z88JbdGyD8jB822hefopzbqhQXaL3QImRA |
link.rule.ids | 230,315,786,790,891,27957,27958 |
linkProvider | Flying Publisher |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Attenuation+of+electrical+remodelling+in+chronic+atrial+fibrillation+following+oral+treatment+with+verapamil&rft.jtitle=Europace+%28London%2C+England%29&rft.au=Meurling%2C+C+J&rft.au=Ingemansson%2C+M+P&rft.au=Roijer%2C+A&rft.au=Carlson%2C+J&rft.date=1999-10-01&rft.issn=1099-5129&rft.volume=1&rft.issue=4&rft.spage=234&rft.epage=241&rft_id=info:doi/10.1053%2Feupc.1999.0055&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1099-5129&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1099-5129&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1099-5129&client=summon |